Israeli pain monitoring start-up Medasense Biometrics has raised $18m in a Series C round from Sabadell Asabys venture capital company, Israeli family offices and returning investors Baxter Ventures, Olive Tree Ventures and LGL Capital.
The company develops NOL technology for pain-response monitoring. Using multi-parametric sensor platform and advanced artificial intelligence (AI) algorithms, the technology converts complicated data into a patient’s ‘Signature of Pain’.
Medasense’s technology is now used in operating rooms and critical care settings, where patients are under anaesthesia and unable to communicate. It enables clinicians to personalise treatment, control pain and avoid an overdose.
